-
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH.
Prenat Diagn 2005;25:927-9. -
Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations.
Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH.
Prenat Diagn 2005;25:365-9. -
Increased nuchal translucency with normal karyotype.
Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1005-21. -
First-Trimester Screening for Chromosomal Abnormalities.
Nicolaides KH.
Semin Perinatol 2005;29:190-4. -
Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
Ultrasound Obstet Gynecol 2005;25:221-6. -
Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A.
Am J Obstet Gynecol 2005;193:322-6. -
Down syndrome screening marker levels in women with a previous aneuploidy pregnancy.
Cuckle HS, Spencer K, Nicolaides KH.
Prenat Diagn 2005;25:47-50. -
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
Prenat Diagn 2005;25:977-83. -
Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1761-7. -
Relation between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype.
Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;26:154-7. -
Pathophysiology of increased nuchal translucency in chromosomally abnormal fetuses.
von Kaisenberg CS, Brand-Saberi B, Jonat W, Nicolaides KH.
Der Gynäkologe 1999;32:193-199. -
Lymphatic vessel hypoplasia in fetuses with Turner syndrome.
von Kaisenberg CS, Nicolaides KH, Brand-Saberi B.
Hum Reprod 1999;14:823-6. -
Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta -hCG and PAPP-A at 10-14 weeks of gestation.
Tul N, Spencer K, Noble P, Chan C, Nicolaides K.
Prenat Diagn 1999;19:1035-42. -
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;13:231-7. -
Increased nuchal translucency in trisomy 13 fetuses at 10-14 weeks of gestation.
Snijders RJ, Sebire NJ, Nayar R, Souka A, Nicolaides KH.
Am J Med Genet 1999;86:205-7. -
Nuchal translucency as a marker of congenital heart disease.
Perdu M, Hyett JA, Sharland G, Snijders RS, Nicolaides KH.
Contracept Fertil Sex 1999;27:I-V. -
Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks.
Matias A, Huggon I, Areias JC, Montenegro N, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;14:307-10. -
Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study.
Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH.
BMJ 1999;318:81-5.